Overview

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Status:
NOT_YET_RECRUITING
Trial end date:
2030-08-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).
Phase:
PHASE2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration
Collaborators:
Memorial Sloan Kettering Cancer Center
Royal Marsden NHS Foundation Trust
Treatments:
tebentafusp